Table 3.

Outcomes.

	n	Month #1				Month #3				Month #6
		ECL (cells/mm2)	ECL (%)	SD	p-value	ECL (cells/mm2)	ECL (%)	SD	p-value	ECL (cells/mm2)	ECL (%)	SD	p-value
Controls	12	1,199	37	497		1,422	44	474		1,178	36	398
APP	18	806	25	414	0.02	1,059	33	446	0.02	979	30	373	0.11
aPRP	8	790	25	377	0.06	1,061	33	332	0.04	988	31	435	0.15
PRGF-Endoret	10	822	25	446	0.03	1,057	32	645	0.05	969	30	497	0.17

Pachymetry		(um)		SD	p-value	(um)		SD	p-value	(um)		SD	p-value
Controls	12	565		66		507		33		519		57
APP	18	529		72	0.11	514		41	0.34	505		43	0.24
aPRP	8	531		38	0.11	528		37	0.12	511		38	0.37
PRGF- Endoret	10	526		84	0.14	500		42	0.34	498		51	0.21

Hexagonality		(%)		SD	p-value	(%)		SD	p-value	(%)		SD	p-value
Controls	12	33		5.6		34		6.9		38		9.8
APP	18	39		4.2	0.005	38		6.7	0.05	40		6.9	0.36
aPRP	8	38		2.8	0.062	36		9.8	0.2	38		5.1	0.46
PRGF-Endoret	10	39		4.78	0.009	40		6.2	0.03	41		8.6	0.25

ECD, endothelial cell density; ECL, endothelial cell loss; SD, standard deviation; APP, autologous plasma products; aPRP, activated platelet rich plasma; PRGF-Endoret, plasma rich in growth factors. Bold value denotes significance.